PaceMate Acquires Medtronic Paceart Optima™ System, Bringing Complementary Capabilities to Cardiac Data Management

“After a comprehensive evaluation, we are confident PaceMate is the best organization to service Paceart customers and their future cardiac data workflow needs,” said Kweli P. Thompson, M.D., M.P.H., senior vice president and president, Medtronic Cardiac Rhythm Management. “PaceMate offers best-in-class cardiac data management solutions and will provide excellent ongoing support to Paceart customers.”

PaceMate, a pioneer in cardiac data management and remote monitoring, announced today the acquisition of the Paceart Optima™ system, an on-premises cardiac workflow solution from Medtronic (NYSE: MDT.) This strategic move significantly expands PaceMate’s reach globally, adding nearly 1,000 clinic locations worldwide. This further enhances PaceMate’s ability to provide the leading and most comprehensive cardiac remote monitoring solution, continuing its position as the preferred partner in advanced cardiac data management.

“After a comprehensive evaluation, we are confident PaceMate is the best organization to service Paceart customers and their future cardiac data workflow needs,” said Kweli P. Thompson, M.D., M.P.H., senior vice president and president, Medtronic Cardiac Rhythm Management. “PaceMate offers best-in-class cardiac data management solutions and will provide excellent ongoing support to Paceart customers.”

Medtronic Cardiac Rhythm Management and PaceMate will collaborate closely to ensure a seamless transition and maintain exceptional service for Paceart customers. “Our shared values, dedication to customer experience, and commitment to exceptional patient-centric cardiac solutions make this agreement a perfect fit,” said Tripp Higgins, CEO of PaceMate. “Paceart customers will benefit from the continued support of Paceart employees transitioning to PaceMate, as well as enhanced service delivery and innovation. We are excited to set a new standard in the market by combining the strengths of both technologies for unparalleled support and advancement.”

PaceMate delivers the industry’s leading comprehensive end-to-end platform, supporting the full spectrum of cardiac device types, including implantables, ambulatory monitors, heart failure devices, and remote patient monitors. This is paired with a complete suite of flexible solutions, including software, patient communications, and clinical service support.

PaceMate’s flagship product, PaceMateLIVE™, is recognized as the best-in-class remote cardiac monitoring software, leveraging powerful EHR integrations for seamless implementation, intuitive use, and intelligent patient prioritization. With the leading robust, research-grade data set, healthcare organizations have access to the most advanced tools for optimizing clinic operations and leveraging patient-centric data to conduct ground-breaking research. This acquisition complements PaceMate and brings it to the forefront of global cardiac care, enabling better patient outcomes and global innovation.

More

Artificial Intelligence Tools Make Education Materials More Patient Friendly

“Our study shows that widely used large language models have the potential to transform patient education materials into more readable content, which is essential for patient empowerment and better health outcomes,” said Study senior author Jonah Feldman, MD, medical director of transformation and informatics at NYU Langone.

CorWave Completes 6-Month In Vivo Study for Clinical Trials Initiation

In vivo studies demonstrated the pump’s successful operation for a period of up to six months. Additionally, nine chronic ovine implants were conducted for 60 days with no device failure or sign of thrombosis at explant. These significant milestones mark the final stage of CorWave’s preclinical development, paving the way for its First-In-Human study.